RESUMEN
Despite global recommendations for influenza vaccination of high-risk, target populations, few low and middle-income countries have national influenza vaccination programs. Between 2012 and 2017, Lao PDR planned and conducted a series of activities to develop its national influenza vaccine program as a part of its overall national immunization program. In this paper, we review the underlying strategic planning for this process, and outline the sequence of activities, research studies, partnerships, and policy decisions that were required to build Laos' influenza vaccine program. The successful development and sustainability of the program in Laos offers lessons for other low and middle-income countries interested in initiating or expanding influenza immunization.
Asunto(s)
Programas de Inmunización , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Vacunación/estadística & datos numéricos , Humanos , Programas de Inmunización/legislación & jurisprudencia , Programas de Inmunización/métodos , Vacunas contra la Influenza/provisión & distribución , Laos , Pobreza , Informe de InvestigaciónRESUMEN
The inhibitor of apoptosis (IAP) proteins have pivotal roles in cell proliferation and differentiation, and antagonizing IAPs in certain cancer cell lines results in induction of cell death. A variety of IAP antagonist compounds targeting the baculovirus IAP protein repeat 3 (BIR3) domain of cIAP1have advanced into clinical trials. Here we sought to compare and contrast the biochemical activities of selected monovalent and bivalent IAP antagonists with the intent of identifying functional differences between these two classes of IAP antagonist drug candidates. The anti-cellular IAP1 (cIAP1) and pro-apoptotic activities of monovalent IAP antagonists were increased by using a single covalent bond to combine the monovalent moieties at the P4 position. In addition, regardless of drug concentration, treatment with monovalent compounds resulted in consistently higher levels of residual cIAP1 compared with that seen following bivalent compound treatment. We found that the remaining residual cIAP1 following monovalent compound treatment was predominantly tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2)-associated cIAP1. As a consequence, bivalent compounds were more effective at inhibiting TNF-induced activation of p65/NF-κB compared with monovalent compounds. Moreover, extension of the linker chain at the P4 position of bivalent compounds resulted in a decreased ability to degrade TRAF2-associated cIAP1 in a manner similar to monovalent compounds. This result implied that specific bivalent IAP antagonists but not monovalent compounds were capable of inducing formation of a cIAP1 E3 ubiquitin ligase complex with the capacity to effectively degrade TRAF2-associated cIAP1. These results further suggested that only certain bivalent IAP antagonists are preferred for the targeting of TNF-dependent signaling for the treatment of cancer or infectious diseases.
RESUMEN
OBJECTIVE: To establish the preterm infant hospitalization risks from respiratory syncytial virus (RSV) in New Zealand and the net cost per hospitalization averted by palivizumab. METHODS: The 437 infants born < 32 weeks' gestation in 1997 and treated at five major neonatal units were identified. Subsequent admissions during the next 2 years for bronchiolitis, pneumonia and croup were tracked, and information collected on RSV tests performed. Data on the length of stay and hospital costs were used to calculate the potential net cost per hospitalization averted associated with the use of palivizumab and the number needed to treat (NNT) to prevent one hospitalization. RESULTS: Estimated RSV readmission risk before 1 year corrected age in infants < 32 weeks' gestation discharged home on oxygen, and those " 28 weeks' gestation, or between 29 and 31 weeks' gestation with or without chronic lung disease was 42%, 23%, 19%, 10% and 8%, respectively. The NNT with palivizumab to prevent one hospitalization ranged from six to 26 across subgroups. Mean (range) net cost per hospitalization averted was 60,000 New Zealand dollars ($28,000-$166,700). In no subgroup would prophylaxis result in net cost saving. Prophylaxis for all NZ infants " 28 weeks' gestation would cost approximately $1,090,000 net and prevent 29 hospitalizations annually, being equivalent to $37,000 net per hospitalization averted, with eight infants treated to prevent one hospitalization. Alternative assumptions about cost and efficacy failed to alter these findings. CONCLUSION: If value is placed on preventing morbidity, the priority groups for palivizumab prophylaxis are preterm infants discharged home on oxygen, followed by preterm infants of 28 weeks' gestation or less.
Asunto(s)
Anticuerpos Monoclonales/economía , Antivirales/economía , Costos de Hospital , Recien Nacido Prematuro , Unidades de Cuidado Intensivo Neonatal/economía , Infecciones por Virus Sincitial Respiratorio/prevención & control , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Antivirales/uso terapéutico , Análisis Costo-Beneficio , Humanos , Recién Nacido , Modelos Econométricos , Nueva Zelanda/epidemiología , Palivizumab , Readmisión del Paciente/economía , Infecciones por Virus Sincitial Respiratorio/epidemiología , RiesgoAsunto(s)
Neoplasias Óseas/secundario , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/mortalidad , Proteínas de Neoplasias/biosíntesis , Hormona Paratiroidea/metabolismo , Biosíntesis de Proteínas , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Óseas/metabolismo , Neoplasias de la Mama/patología , Femenino , Humanos , Inmunohistoquímica , Metástasis Linfática , Persona de Mediana Edad , Oportunidad Relativa , Proteína Relacionada con la Hormona Paratiroidea , Pronóstico , Modelos de Riesgos Proporcionales , Factores de Riesgo , Análisis de SupervivenciaRESUMEN
Rhinoviruses are the most common causes of viral respiratory infections and complications caused by viral respiratory infections in patients with underlying lung disease. Major recent therapeutic advances include the development of capsid-function inhibitors (pleconaril), inhibitors of 3C protease (AG7088), and recombinant soluble intercellular adhesion molecule (sICAM)-1, all of which exhibit potent antirhinoviral activity in vitro and varying activity in clinical trials. Pleconaril and AG7088 have shown the most promise and are the most advanced in clinical trials.
Asunto(s)
Antivirales/uso terapéutico , Infecciones por Picornaviridae/tratamiento farmacológico , Infecciones por Picornaviridae/virología , Rhinovirus/efectos de los fármacos , Animales , Antivirales/farmacología , Cápside/antagonistas & inhibidores , Cápside/fisiología , Humanos , Inhibidores de la Síntesis de la Proteína/farmacología , Inhibidores de la Síntesis de la Proteína/uso terapéutico , Receptores Virales/antagonistas & inhibidores , Rhinovirus/fisiología , Proteínas Virales/antagonistas & inhibidores , Proteínas Virales/biosíntesis , Virión/efectos de los fármacosRESUMEN
The effect of hormone replacement therapy (HRT) on presentation and diagnoses of post-menopausal women has been examined by a retrospective review of patients presenting to a symptomatic Breast Clinic over a 5-year period. Sixty-seven post-menopausal women aged less than 65 years taking hormone replacement therapy for more than 6 months were compared with 144 post-menopausal women aged less than 65 years not taking hormone replacement therapy. There was no difference in the pattern of presentation, rate of intervention or final diagnoses between these two groups. HRT does not appear to effect the pattern of presentation of benign breast disease in post-menopausal women.
RESUMEN
BACKGROUND: Although the male condom provides a reliable means of preventing HIV transmission, a broader choice of methods is required particularly in circumstances where the negotiation of condom use is difficult. Development of new products that may be effective as topical vaginal microbicides is the focus of a great deal of research activity currently. The novel agent PRO 2000, a naphthalene sulphonate derivative with in vitro activity against HIV and other sexually transmissible pathogens, is one such compound. We have studied the local and systemic safety and tolerance of a vaginal gel formulation of this agent at two concentrations (0.5% and 4%) over a 2 week period of daily exposure in two cohorts of healthy sexually abstinent women (one in London, UK, and the other in Antwerp, Belgium). METHODS: This was a randomised, placebo controlled, double blind, three arm clinical trial conducted on two sites. Macroscopic evidence of genital epithelial changes was sought using colposcopy and evidence of microscopic inflammation was acquired using high vaginal biopsy from predetermined sites (UK cohort only). Blood levels of PRO 2000 were measured and laboratory safety tests, including coagulation screens, were performed. The impact on vaginal ecology was also assessed. RESULTS: 73 women were enrolled across both sites (36 UK, 37 Belgium); 24, 24, 25 in the 4%, 0.5%, and placebo groups respectively. Of these, 70 completed 2 weeks' exposure to the study gel. Three (all in the 4% group) withdrew owing to adverse events which were possibly or probably gel related. Cervicovaginal abrasion was seen colposcopically in three subjects after 14 days of gel use (two in the 4% group and one in the placebo group). Genital ulceration was not seen during gel use in any of the subjects who completed the study. Histological evaluation of vaginal biopsy samples (36 women only) showed evidence of increased inflammatory signs in one participant of the 4.0% group. One volunteer in the placebo group had moderate inflammation at screening and at follow up. Severe inflammation was not seen among any of the subjects tested. Plasma levels of PRO 2000 and laboratory safety tests showed no evidence of systemic absorption. No impact was seen on normal vaginal ecology in the UK cohort where samples were taken 12 hours after the last gel application. CONCLUSION: In this phase I study PRO 2000 gel was found to be generally well tolerated with promising local and systemic safety profiles. The 0.5% gel was better tolerated than the 4% gel as fewer genital epithelial adverse events were seen in the former. Phase II studies are about to begin in sexually active women.
Asunto(s)
Antivirales/efectos adversos , Infecciones por VIH/prevención & control , Naftalenosulfonatos/efectos adversos , Polímeros/efectos adversos , Enfermedades Vaginales/inducido químicamente , Administración Intravaginal , Adolescente , Adulto , Antivirales/administración & dosificación , Bélgica , Estudios de Cohortes , Método Doble Ciego , Células Epiteliales/patología , Femenino , Geles , Humanos , Persona de Mediana Edad , Naftalenosulfonatos/administración & dosificación , Satisfacción del Paciente , Polímeros/administración & dosificación , Abstinencia Sexual , Resultado del Tratamiento , Reino UnidoRESUMEN
GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an important role in growth and maintenance of malignancies. Preclinically, GEM231 inhibited human cancer xenografts either alone or synergistically with chemotherapeutic agents and has demonstrated an improved metabolic stability and safety profile compared to the first-generation compounds. Objectives of this study were to define the safety profile and pharmacokinetics of GEM231 administered as 2-h IV infusions twice weekly in patients with refractory solid tumors. Fourteen patients (13 evaluable for safety) received escalating doses of GEM231 at 20-360 mg/m2 (2.5-9 mg/kg). Tumor histologies included non-small cell lung cancer, renal cell cancer, sarcoma, and others. The plasma pharmacokinetics of GEM231 were linear and predictable. Maximum plasma concentration (Cmax) reached 50-70 microg/ml (8-13 microM) at dose 360 mg/m2 and 27-32 microg/ml at dose 240 mg/m2. The plasma half-life was about 1.5 h. The only clinical toxicities were transient grade I-II fever and fatigue at doses > or = 240 mg/m2. There was no treatment-related complement activation or thrombocytopenia at any dose level, except with the first dose in one patient who had pre-existing borderline thrombocytopenia. Transient activated partial thrombin time prolongation occurred at doses > or =160 mg/m2. Dose-limiting toxicities included transient activated partial thrombin time prolongation (one of three patients at 360 mg/m2) and cumulative reversible transaminase elevation (three of three patients at 360 mg/m2 and three of six patients at 240 mg/m2 during weeks 3-10). One patient with colon cancer had stabilization of a previously rising carcinoembryonic antigen. Thus, in this first clinical evaluation of a mixed-backbone oligonucleotide in cancer patients, high plasma concentrations of GEM231 were well tolerated without significant acute toxicities, but prolonged treatment was associated with reversible transaminitis. Although 240 mg/m2 by 2-h infusion twice weekly was safe for a 4-week treatment duration, alternative dosing schedules are being tested to minimize the cumulative toxicity, which will be essential to extend the duration of therapy at the highest GEM231 dose tested.
Asunto(s)
Proteínas Quinasas Dependientes de AMP Cíclico/antagonistas & inhibidores , Neoplasias/tratamiento farmacológico , Oligonucleótidos Antisentido/farmacocinética , Anciano , Alanina Transaminasa/sangre , Alanina Transaminasa/efectos de los fármacos , Área Bajo la Curva , Secuencia de Bases , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Células Renales/tratamiento farmacológico , Carcinoma de Células Renales/metabolismo , Subunidad RIalfa de la Proteína Quinasa Dependiente de AMP Cíclico , Proteínas Quinasas Dependientes de AMP Cíclico/genética , Diarrea/inducido químicamente , Relación Dosis-Respuesta a Droga , Resistencia a Antineoplásicos , Fatiga/inducido químicamente , Femenino , Fiebre/inducido químicamente , Humanos , Infusiones Intravenosas , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/metabolismo , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/metabolismo , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Neoplasias/metabolismo , Oligonucleótidos Antisentido/efectos adversos , Oligonucleótidos Antisentido/química , Tiempo de Tromboplastina Parcial , Sarcoma/tratamiento farmacológico , Sarcoma/metabolismo , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Antivirales/uso terapéutico , Oxadiazoles/uso terapéutico , Infecciones por Picornaviridae/tratamiento farmacológico , Antivirales/farmacología , Enterovirus/efectos de los fármacos , Humanos , Meningitis Viral/tratamiento farmacológico , Meningitis Viral/fisiopatología , Oxadiazoles/farmacología , OxazolesRESUMEN
Crystallographic studies of human rhinovirus 14 (HRV14) crystals soaked with fragments of antiviral WIN compounds, at high concentrations (82-200 micrograms/ml), show the compounds bind into the hydrophobic beta-barrel (WIN pocket) of VP1. Two of these short compounds (5-[3,5-dimethyl-4-hydroxyphenyl]-2-methyltetrazole and phenol oxazoline) cause conformational changes in the virus similar to the active, longer WIN compounds. In addition, thermostabilization studies suggest these short WIN compounds provide some stability to the HRV14 capsid. We conclude that the short compounds appear to mimic the cellular cofactors observed in the hydrophobic pocket of VP1 for some picornaviruses. Both cofactors and short WIN compounds bind into the pocket, cause conformational changes in VP1, and provide a small degree of virion stabilization but are unlikely to inhibit attachment. Three specific binding sites for dimethyl sulfoxide (DMSO), used as solvent, were also identified. One of the DMSO molecules binds into the drug binding pocket near the pocket opening, while the other two bind in the canyon near the VP1 protomer-protomer interface.
Asunto(s)
Antivirales/química , Rhinovirus/ultraestructura , Antivirales/farmacología , Cápside/química , Cápside/metabolismo , Proteínas de la Cápside , Clorobencenos/química , Clorobencenos/farmacología , Cristalografía por Rayos X , Estructura Molecular , Oxazoles/química , Oxazoles/farmacología , Rhinovirus/química , Rhinovirus/efectos de los fármacos , Tetrazoles/química , Tetrazoles/farmacología , TermodinámicaRESUMEN
BACKGROUND: Rhinoviruses and the homologous polioviruses have hydrophobic pockets below their receptor-binding sites, which often contain unidentified electron density ('pocket factors'). Certain antiviral compounds also bind in the pocket, displacing the pocket factor and inhibiting uncoating. However, human rhinovirus (HRV)14, which belongs to the major group of rhinoviruses that use intercellular adhesion molecule-1 (ICAM-1) as a receptor, has an empty pocket. When antiviral compounds bind into the empty pocket of HRV14, the roof of the pocket, which is also the floor of the receptor binding site (the canyon), is deformed, preventing receptor attachment. The role of the pocket in viral infectivity is not known. RESULTS: We have determined the structure of HRV16, another major receptor group rhinovirus serotype, to atomic resolution. Unlike HRV14, the pockets contain electron density resembling a fatty acid, eight or more carbon atoms long. Binding of the antiviral compound WIN 56291 does not cause deformation of the pocket, although it does prevent receptor attachment. CONCLUSIONS: We conjecture that the binding of the receptor to HRV16 can occur only when the pocket is temporarily empty, when it is possible for the canyon floor to be deformed downwards into the pocket. We further propose that the role of the pocket factor is to stabilize virus in transit from one host cell to the next, and that binding of ICAM-1 traps the pocket in the empty state, destabilizing the virus as required for uncoating.
Asunto(s)
Cápside/química , Conformación Proteica , Estructura Secundaria de Proteína , Rhinovirus/química , Secuencia de Aminoácidos , Antivirales/toxicidad , Proteínas de la Cápside , Moléculas de Adhesión Celular/química , Moléculas de Adhesión Celular/metabolismo , Humanos , Molécula 1 de Adhesión Intercelular , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Datos de Secuencia Molecular , Receptores Virales/química , Receptores Virales/fisiología , Rhinovirus/efectos de los fármacos , Rhinovirus/fisiología , Homología de Secuencia de AminoácidoRESUMEN
The rhinovirus and enterovirus members of the picornavirus family are responsible for the majority of the mild upper respiratory infections most often referred to as the common cold as well as more serious illnesses including myocarditis. Much progress has been made in the identification and development of antiviral agents which specifically target the capsid of the picornaviruses. Preclinical and clinical efficacy data will be discussed on the WIN series of antiviral agents which were the result of a conventional drug discovery approach. The design of new agents is being assisted by the availability of atomic resolution data on the interaction of this class of antiviral agents with the viral capsid.
Asunto(s)
Antivirales/química , Antivirales/farmacología , Picornaviridae/efectos de los fármacos , Animales , Diseño de Fármacos , HumanosRESUMEN
A historical review of x-ray crystallography introduces basic concepts and describes the potential of this science to the rational design of antiviral agents. Following a brief introduction to the study of antiviral compounds that inhibit early stages of rhino- and enteroviral infections, the impact of structural studies on rational drug design is discussed in relation to known viral structures.
Asunto(s)
Antivirales/química , Cristalografía por Rayos X , Diseño de Fármacos , Antivirales/farmacología , Rhinovirus/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
The human rhinoviruses are the leading cause of the ubiquitous, mild, and self-limiting infections generally referred to as the common cold. Considerable research effort has been expended in the search for well tolerated antiviral agents capable of preventing and treating the common cold. Although no antirhinovirus drug is yet commercially available, considerable progress has been made in the discovery and development of novel, viral specific inhibitors of rhinovirus replication. This report reviews the history and current status of the research that has focused on inhibitors of the early steps in the virus life cycle: attachment to the cellular receptor and uncoating of the viral RNA. Molecules directed at these targets currently possess the greatest potential for generating a safe and efficacious treatment for the rhinovirus common cold.
Asunto(s)
Antivirales/uso terapéutico , Resfriado Común/tratamiento farmacológico , Infecciones por Picornaviridae/tratamiento farmacológico , HumanosRESUMEN
The binding affinities (Kds) and the rates of association and dissociation of members of a chemical class of antiviral compounds at their active sites in human rhinovirus type 14 (HRV-14) were determined. On the basis of analysis by LIGAND, a nonlinear curve-fitting program, of saturation binding experiments with HRV-14, the Kds for Win 52084, Win 56590, disoxaril (Win 51711), and Win 54954 were found to be 0.02, 0.02, 0.08, and 0.22 microM, respectively. The independently determined kinetic rates of association and dissociation resulted in calculated Kd values which were in agreement with the Kd values determined in saturation binding experiments. Scatchard plots of each of four compounds for the binding data indicated that approximately 40 to 60 molecules were bound per HRV-14 virion. Hill plots showed no evidence of cooperativity in binding. Furthermore, the antiviral activities (MICs in plaque reduction assays with HRV-14) for this limited series of compounds (n = 4) correlated well (r = 0.997) with the observed Kds. Likewise, the absence of detectable binding of Win 54954 to the drug-resistant mutant HRV-14 (Leu-1188) corresponded to a lack of antiviral activity. The positive relationship between the antiviral activities and the Kds that were determined may have implications for the molecular design of capsid-binding antirhinovirus drugs.